Louise Kooij - Sep 27, 2024 Form 4 Insider Report for NewAmsterdam Pharma Co N.V. (NAMS)

Role
Chief Accounting Officer
Signature
/s/ Louise Kooij
Stock symbol
NAMS
Transactions as of
Sep 27, 2024
Transactions value $
-$707,400
Form type
4
Date filed
10/1/2024, 05:23 PM
Previous filing
Jan 3, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NAMS Ordinary Shares Options Exercise +45K 45K Sep 27, 2024 Direct F1, F2
transaction NAMS Ordinary Shares Sale -$707K -45K -100% $15.72 0 Oct 1, 2024 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NAMS Option (right to buy) Options Exercise $0 -45K -21.12% $0.00 168K Sep 27, 2024 Ordinary Shares 45K Direct F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The exercise price of the option is EUR 1.16392.
F2 The securities were previously held indirectly by the Reporting Person through LouFre Management B.V. ("LouFre") for the benefit of the Reporting Person. The Reporting Person had the sole pecuniary interest in the securities.
F3 The option was granted on November 22, 2022 to replace an option originally granted on July 6, 2021 which was cancelled in connection with the consummation of NewAmsterdam Pharma Company N.V.'s business combination with Frazier Lifesciences Acquisition Corporation. 60,879 of the shares underlying the option immediately vested on the grant date. 25% of the remaining shares underlying the option vested on January 1, 2021, the one-year anniversary of vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date.